Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious
Open Orphan PLC (AIM:ORPH) CEO share purchase
Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious
Open Orphan plc (AIM:ORPH) Upcoming Scientific Presentations
Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious
Open Orphan PLC (AIM:ORPH) Press Speculation
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the media
Open Orphan PLC (AIM:ORPH) Interim results and Trading Update
Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and the world leader in testing
Open Orphan PLC (AIM:ORPH) Intention to change name to hVIVO plc
Planned name change to hVIVO plc
Open Orphan PLC (AIM:ORPH) Clinical laboratories achieves CAP accreditation
Confirms hVIVO laboratories’ high standard of excellence
Open Orphan PLC (AIM:ORPH) £10.4m full-service contract signed with existing Big Pharma client
hVIVO to develop new influenza challenge strain to test oral antiviral candidate
Open Orphan PLC (AIM:ORPH) £6.2m Influenza human challenge study contract
Open Orphan plc (AIM: ORPH), is a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials.
Open Orphan PLC (AIM:ORPH) Omicron human challenge model
hVIVO to develop the world’s first Omicron human challenge model
Open Orphan PLC (AIM:ORPH) £7.2m RSV human challenge study contract
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces thathVIVO,
